Pyxis Oncology Extends Cash Runway to Q2 2027, Sets Fall Data Readouts for MICVO
PYXS has more than doubled off its 52-week low of $1.
Summary
Pyxis Oncology reported Q2 2026 results and provided updated clinical timelines for its lead asset MICVO. The company now expects to report updated monotherapy data in 2L+ R/M HNSCC in Fall 2026, including detailed dose cap analyses, and combination data with pembrolizumab in Q4 2026. The recent $50M upfront private placement, combined with existing cash, extends the runway into Q2 2027, a meaningful improvement from the prior Q4 2026 estimate. This follows the July 2 completion of the financing and addresses the going concern risk highlighted in the last 10-Q. The extended runway and near-term data catalysts position the company for potential value inflection, though the data readouts remain binary events.
Updates
· SEC 10-Q — The 10-Q reports cash, cash equivalents, and marketable debt securities of $33.0 million as of June 30, 2026, and a net loss of $25.3 million for Q2 2026.
At the time of this announcement, PYXS was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.5M. The 52-week trading range was $1.00 to $5.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.